These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 20852004

  • 1. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.
    Ward RM, Kearns GL, Tammara B, Bishop P, O'Gorman MA, James LP, Katz MH, Maguire MK, Rath N, Meng X, Comer GM.
    J Clin Pharmacol; 2011 Jun; 51(6):876-87. PubMed ID: 20852004
    [Abstract] [Full Text] [Related]

  • 2. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.
    Tammara BK, Sullivan JE, Adcock KG, Kierkus J, Giblin J, Rath N, Meng X, Maguire MK, Comer GM, Ward RM.
    Clin Pharmacokinet; 2011 Aug; 50(8):541-50. PubMed ID: 21740077
    [Abstract] [Full Text] [Related]

  • 3. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).
    Ward RM, Tammara B, Sullivan SE, Stewart DL, Rath N, Meng X, Maguire MK, Comer GM.
    Eur J Clin Pharmacol; 2010 Jun; 66(6):555-61. PubMed ID: 20306184
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
    James L, Walson P, Lomax K, Kao R, Varughese S, Reyes J, Study 119 Pediatric Trial Investigators.
    Clin Ther; 2007 Sep; 29(9):2082-92. PubMed ID: 18035206
    [Abstract] [Full Text] [Related]

  • 5. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW, Ballard ED, Koch FK, Gautille TC, Bagin RG.
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M, Wu J, Perez MC.
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [Abstract] [Full Text] [Related]

  • 7. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents.
    Kearns GL, Blumer J, Schexnayder S, James LP, Adcock KG, Reed MD, Daniel JF, Gaedigk A, Paul J.
    J Clin Pharmacol; 2008 Nov; 48(11):1356-65. PubMed ID: 18664620
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial.
    van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans ME.
    Digestion; 2010 Nov; 81(1):43-52. PubMed ID: 20029208
    [Abstract] [Full Text] [Related]

  • 9. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
    Sandström M, Davidson G, Tolia V, Sullivan JE, Långström G, Lundborg P, Brown K.
    Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
    [Abstract] [Full Text] [Related]

  • 10. Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.
    Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL, Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    J Pediatr; 2018 Feb; 193():102-108.e1. PubMed ID: 29389444
    [Abstract] [Full Text] [Related]

  • 11. [Pharmacokinetics of the proton pump inhibitors and psychological status in patients as factors that influence the efficiency of treatment of GERD with pantoprazole].
    Bordin DS, Masharova AA, Sil'vestrova SIu, Firsova LD, Safonova OV, Petrakov AV, Kozhurina TS, Valitova ER, Ianova OB.
    Eksp Klin Gastroenterol; 2010 Feb; (9):90-6. PubMed ID: 21427932
    [Abstract] [Full Text] [Related]

  • 12. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
    Baker R, Tsou VM, Tung J, Baker SS, Li H, Wang W, Rath N, Maguire MK, Comer GM.
    Clin Pediatr (Phila); 2010 Sep; 49(9):852-65. PubMed ID: 20522615
    [Abstract] [Full Text] [Related]

  • 13. Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.
    Jiao HW, Sun LN, Li YQ, Yu L, Zhang HW, Wang MF, Yu LY, Yuan ZQ, Xie LJ, Chen J, Meng L, Zhang XH, Wang YQ.
    Eur J Clin Pharmacol; 2018 Mar; 74(3):257-265. PubMed ID: 29167917
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR.
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
    [Abstract] [Full Text] [Related]

  • 16. A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents.
    Shakhnovich V, Brian Smith P, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL, Cohen-Wolkowiez M, Best Pharmaceuticals for Children Act–Pediatric Trials Network.
    Paediatr Drugs; 2018 Oct; 20(5):483-495. PubMed ID: 30097906
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D, Bagin R, Goldlust B, Major J, Hepburn B.
    Aliment Pharmacol Ther; 2005 Jun 15; 21(12):1467-74. PubMed ID: 15948814
    [Abstract] [Full Text] [Related]

  • 18. [Panum (pantoprazole) effectiveness in the treatment of patients with GERD].
    Masharova AA, Ianova OB, Valitova ÉR, Kim VA, Zelenkin SA.
    Eksp Klin Gastroenterol; 2011 Jun 15; (4):81-5. PubMed ID: 21916207
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.
    Winter H, Kum-Nji P, Mahomedy SH, Kierkus J, Hinz M, Li H, Maguire MK, Comer GM.
    J Pediatr Gastroenterol Nutr; 2010 Jun 15; 50(6):609-18. PubMed ID: 20400912
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.